Form 4: Kiniksa Pharmaceuticals International Executive Receives Sto
Insider Transaction (Form 4)
John F. Paolini, CHIEF MEDICAL OFFICER of Kiniksa Pharmaceuticals International, plc, reported multiple transactions in common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 2,497 Class A Ordinary Share on September 1, 2026; holds 68,120 after (Direct).
- Option exercise/conversion: acquired 1,624 Class A Ordinary Share on September 1, 2026; holds 69,744 after (Direct).
- Option exercise/conversion: acquired 1,750 Class A Ordinary Share on September 1, 2026; holds 71,494 after (Direct).
- Option exercise/conversion: acquired 2,457 Class A Ordinary Share on September 1, 2026; holds 73,951 after (Direct).
- Tax/exercise-price withholding: disposed of 4,029 Class A Ordinary Share at $79.28 ($319,419) on September 1, 2026; holds 69,922 after (Direct).
- Grant/award: acquired 6,700 Restricted Share Unit on September 1, 2026; holds 6,700 after (Direct).
- Grant/award: acquired 26,750 Share Option on September 1, 2026; holds 26,750 after (Direct).
- Option exercise/conversion: disposed of 2,457 Restricted Share Unit on September 1, 2026; holds 7,371 after (Direct).
- Option exercise/conversion: disposed of 1,750 Restricted Share Unit on September 1, 2026; holds 3,500 after (Direct).
- Option exercise/conversion: disposed of 1,624 Restricted Share Unit on September 1, 2026; holds 1,624 after (Direct).
- Option exercise/conversion: disposed of 2,497 Restricted Share Unit on September 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
John F. Paolini — Officer (CHIEF MEDICAL OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Class A Ordinary Share | 2,497 | — | — | 68,120 |
| 2026-09-01 | Option exercise/conversion | Class A Ordinary Share | 1,624 | — | — | 69,744 |
| 2026-09-01 | Option exercise/conversion | Class A Ordinary Share | 1,750 | — | — | 71,494 |
| 2026-09-01 | Option exercise/conversion | Class A Ordinary Share | 2,457 | — | — | 73,951 |
| 2026-09-01 | Tax/exercise-price withholding | Class A Ordinary Share | 4,029 | $79 | $319.4K | 69,922 |
| 2026-09-01 | Grant/award | Restricted Share Unit | 6,700 | — | — | 6,700 |
| 2026-09-01 | Grant/award | Share Option | 26,750 | — | — | 26,750 |
| 2026-09-01 | Option exercise/conversion | Restricted Share Unit | 2,457 | — | — | 7,371 |
| 2026-09-01 | Option exercise/conversion | Restricted Share Unit | 1,750 | — | — | 3,500 |
| 2026-09-01 | Option exercise/conversion | Restricted Share Unit | 1,624 | — | — | 1,624 |
| 2026-09-01 | Option exercise/conversion | Restricted Share Unit | 2,497 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (2,497 shares) |
| 2026-09-01 | Option exercise/conversion (1,624 shares) |
| 2026-09-01 | Option exercise/conversion (1,750 shares) |
| 2026-09-01 | Option exercise/conversion (2,457 shares) |
| 2026-09-01 | Tax/exercise-price withholding (4,029 shares) |
| 2026-09-01 | Grant/award (6,700 shares) |
| 2026-09-01 | Grant/award (26,750 shares) |
| 2026-09-01 | Option exercise/conversion (2,457 shares) |
| 2026-09-01 | Option exercise/conversion (1,750 shares) |
| 2026-09-01 | Option exercise/conversion (1,624 shares) |
| 2026-09-01 | Option exercise/conversion (2,497 shares) |
Keywords
insider transaction, Form 4, KNSA, Kiniksa Pharmaceuticals International, plc, neutral, John F. Paolini
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.